undamentalytics Newsletter

Lynx1 Capital Management LP: insider trades

10% owner at 5 companies we cover. 10 open-market purchases and 1 sale not made under a pre-set plan, reported from June 2, 2023 to October 26, 2026.

Would copying Lynx1 Capital Management LP’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 4 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on July 25, 2025 into $18,116 by November 2, 2026, +59.7% a year. The copy held shares only 100% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $12,035, +15.7% a year (the S&P 500 held throughout made $12,035, +15.7% a year). Beta against the index was 1.68. Twelve months after each report, the average purchase was +0.5% against the S&P 500 (median +0.4%), and 50% beat it. Measured from the trade date, the insider’s own timing, the average was +51.6%.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$5.0k$10.0k$15.0k 20252026 $18.1k$12.0k$12.0k
Copying Lynx1 Capital Management LPS&P 500, same days investedS&P 500, held throughout $10,000 copying Lynx1 Capital Management LP’s open-market purchases from July 25, 2025, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
+59.7%
S&P 500, same days invested
+15.7% (held throughout +15.7%)
Time in shares
100%
Sharpe ratio (S&P 500)
0.95 (0.92)
Biggest drop (S&P 500)
−40% (−9%)
Market sensitivity (beta)
1.68
Purchases copied
6

Trade by trade

Lynx1 Capital Management LP: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 4 +9.6% +13.1% 50% 1 — — Not enough years
Purchases, 6 months after the report 4 +43.6% +56.6% 75% 1 — — Not enough years
Purchases, 12 months after the report 4 +0.5% +0.4% 50% 1 — — Not enough years
Purchases, 12 months after the trade 3 +51.6% +63.1% 67% 1 — — Not enough years
Sales, 3 months after the report 0 — — — — — — Not enough years
Sales, 12 months after the report 0 — — — — — — Not enough years
Sales, 12 months after the trade 0 — — — — — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Tscan Therapeutics, Inc. TCRX —21June 2, 2023December 23, 2025
Passage BIO, Inc. PASG —30November 27, 2024July 24, 2025
Cullinan Therapeutics, Inc. CGEM —20October 10, 2025October 21, 2025
Korro Bio, Inc. KRRO —20August 13, 2026October 26, 2026
Neuphoria Therapeutics Inc. NEUP —10October 23, 2025October 23, 2025

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
October 26, 2026October 22, 2026 KRRO Purchase $884,752 not yetnot yetnot yet
August 13, 2026August 6, 2026 KRRO Purchase $78,815 not yetnot yetnot yet
December 23, 2025December 19, 2025 TCRX Purchase $145,621 not yetnot yetnot yet
October 23, 2025October 21, 2025 NEUP Purchase $3,285,025 −38.1%−60.5%not yet
October 21, 2025October 14, 2025 CGEM Purchase $2,104,584 +50.4%+61.9%+63.1%
October 10, 2025October 8, 2025 CGEM Purchase $9,829,099 +32.1%+56.9%+123.9%
July 24, 2025July 22, 2025 PASG Purchase $733,658 −5.9%−56.2%−32.3%
May 21, 2025May 19, 2025 TCRX Purchase $3,106,553 not yetnot yetnot yet
December 31, 2024December 27, 2024 PASG Purchase $242,869 not yetnot yetnot yet
November 27, 2024November 25, 2024 PASG Purchase $283,839 not yetnot yetnot yet
June 2, 2023May 31, 2023 TCRX Sale $63,904 not yetnot yetnot yet

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Lynx1 Capital Management LP traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.